T-Cell Responses to COVID-19 Vaccines May Benefit Anti-CD20-Treated Lymphoma Patients
Despite an inferior rate of seroconversion, lymphoma patients treated with anti-CD20 therapy did mount T-cell responses.
Chronic Lymphocytic Leukemia News
CHRONIC LYMPHOCYTIC LEUKEMIA ADVISOR
Chronic Lymphocytic Leukemia News
Platelet, Hemoglobin Levels Related to COVID-19 Mortality in Hematologic Malignancies
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
Novel Agents Lead to Changes in Therapeutic Strategies and Sequencing for CLL
Data were analyzed from patients diagnosed with CLL between 2000 and 2020 from 77 institutions affiliated with the ERIC.
Acalabrutinib Effective for Relapsed/Refractory CLL at 3 Years
The findings support the use of acalabrutinib in patients with relapsed/refractory CLL, including those with high-risk features.
Black Patients Less Likely to Receive Novel Agents as First-Line CLL Therapy
Investigators revealed unequal access to novel agents when comparing Black and White patients with CLL.
Lymphadenopathy in CLL Patients Predicts Richter’s Syndrome Risk After Ibrutinib
The retrospective study included 559 patients who had received ibrutinib for CLL, of whom 179 progressed according to iwCLL criteria.
Ibrutinib Plus Venetoclax Produces Superior uMRD Responses in CLL
Researchers presented updated findings from the GLOW trial.
Hospitalization, ED Visits Highest in First Month After CAR T-Cell Infusion
Sixty-seven percent of rehospitalizations occurred within the first month of CAR T-cell infusion.
Third COVID-19 Vaccine Dose Boosts Seroconversion Rate in CLL Patients
Vaccine responses were evaluated after dose 1 for 158 CLL patients, after dose 2 for 506 patients, and after dose 3 for 66 patients.
MRD-Guided Treatment Appears Effective With BOVen Regimen in CLL/SLL
Nearly 90% of patients reached the prespecified MRD endpoint and discontinued treatment after a median of 10 cycles.
Venetoclax-Obinutuzumab vs Rituximab Regimens in Fit CLL Patients
This phase 3 study is designed to compare venetoclax plus obinutuzumab with 1 of 2 rituximab-based regimens in previously untreated CLL.
Zanubrutinib Improves PFS, But May Not Improve OS, in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Researchers sought to determine whether zanubrutinib would improve survival in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Venetoclax-Based Regimens Best CIT in Fit Patients With Chronic Lymphocytic Leukemia
Rates of undetectable MRD were highest with venetoclax plus obinutuzumab or venetoclax plus obinutuzumab and ibrutinib.
Combinations Produced Durable Responses in High-Risk Chronic Lymphocytic Leukemia
One third of patients stopped maintenance therapy because they achieved remission with undetectable minimal residual disease.
CLL Treatment May Increase Risk of Death From COVID-19
There were no significant differences by treatment type.
Ibrutinib Not Recommended Over ‘Watch and Wait’ in Asymptomatic, Early CLL
Ibrutinib improved event-free survival, but its effect on overall survival is unclear.
Breakthrough COVID-19 May Be More Common in Patients With Lymphoid Malignancies
About 81% of patients had lymphoproliferative malignancies.
Survey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
Low Rate of Cardiac Toxicity Reported With Acalabrutinib in CLL
Cardiac adverse events were seen in 17% of patients.
PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia News
Loading... 
Loading...